MedCity News Startup Ozette unveils AI approach to understanding the immune system Ozette applies artificial intelligence to immune monitoring to gain greater insight into a cancer patient's immune system. Beyond informing treatment decisions, the technology can guide drug and diagnostic development. Shares1
Cancer patients receive a check-in to see how their immune cells are working and whether the disease is responding to treatment. This immune monitoring is a routine part of cancer care and it helps guide treatment decisions. Yet current analysis methods remain limited, according to Ali Ansary, co-founder and CEO of startup Ozette. The Seattle-based company aims to take immune monitoring further and it is using artificial intelligence to do it. The approach could accelerate analysis of the immune system, helping clinicians make better diagnostic and treatment decisions. The technology could yield insights not only for cancer care, but also infectious disease, inflammatory disorders, and more, said Ansary, who is an attending physician at the University of Washington Medical Center.